Medicus Pharma Ltd.

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell MDCX and other ETFs, options, and stocks.

About MDCX

Medicus Pharma Ltd. is a biotech life sciences company, which focuses on accelerating the clinical development programs of novel and disruptive therapeutic assets. It develops a product, SkinJectTM, with an indication for basal cell carcinoma. 

CEO
Raza Bokhari
CEORaza Bokhari
Employees
12
Employees12
Headquarters
Toronto, Ontario
HeadquartersToronto, Ontario
Founded
2008
Founded2008
Employees
12
Employees12

MDCX Key Statistics

Market cap
35.17M
Market cap35.17M
Price-Earnings ratio
-0.69
Price-Earnings ratio-0.69
Dividend yield
Dividend yield
Average volume
278.44K
Average volume278.44K
High today
$1.45
High today$1.45
Low today
$1.39
Low today$1.39
Open price
$1.43
Open price$1.43
Volume
20.13K
Volume20.13K
52 Week high
$8.94
52 Week high$8.94
52 Week low
$1.38
52 Week low$1.38

Stock Snapshot

Medicus Pharma Ltd.(MDCX) stock is priced at $1.41, giving the company a market capitalization of 35.17M. It carries a P/E multiple of -0.69.

During the trading session on 2026-01-14, Medicus Pharma Ltd.(MDCX) shares reached a daily high of $1.45 and a low of $1.39. At a current price of $1.41, the stock is +1.7% higher than the low and still -2.8% under the high.

Trading activity shows a volume of 20.13K, compared to an average daily volume of 278.44K.

Over the past 52 weeks, Medicus Pharma Ltd.(MDCX) stock has traded between a high of $8.94 and a low of $1.38.

Over the past 52 weeks, Medicus Pharma Ltd.(MDCX) stock has traded between a high of $8.94 and a low of $1.38.

People also own

Based on the portfolios of people who own MDCX. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the .